Commerce Bank Sells 313 Shares of Qiagen (NYSE:QGEN)

Commerce Bank trimmed its holdings in shares of Qiagen (NYSE:QGEN) by 6.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,927 shares of the company’s stock after selling 313 shares during the period. Commerce Bank’s holdings in Qiagen were worth $225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in QGEN. PEAK6 Investments LLC boosted its stake in shares of Qiagen by 270.0% during the first quarter. PEAK6 Investments LLC now owns 7,925 shares of the company’s stock valued at $341,000 after purchasing an additional 12,587 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Qiagen by 13.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 91,763 shares of the company’s stock valued at $3,945,000 after purchasing an additional 10,683 shares in the last quarter. CWM LLC boosted its stake in shares of Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after purchasing an additional 269 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Qiagen by 14.2% during the second quarter. SG Americas Securities LLC now owns 496,951 shares of the company’s stock valued at $20,420,000 after purchasing an additional 61,815 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft boosted its stake in shares of Qiagen by 88.0% during the second quarter. Baader Bank Aktiengesellschaft now owns 37,602 shares of the company’s stock valued at $1,540,000 after purchasing an additional 17,602 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on QGEN shares. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 17th. Robert W. Baird increased their target price on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Trading Up 1.2 %

NYSE QGEN opened at $43.76 on Thursday. The company has a fifty day simple moving average of $43.32 and a two-hundred day simple moving average of $43.73. The stock has a market cap of $9.99 billion, a P/E ratio of 112.21, a P/E/G ratio of 3.35 and a beta of 0.41. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.